Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03827798 · ClinicalTrials.gov registry record · Phase 2

Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa

A Phase 2 study of Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
248
Enrollment target
20
Study locations

NCT03827798: Active Phase 2 study of Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals.

NCT03827798 is a Phase 2 study of Hidradenitis Suppurativa that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 248 participants, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (58% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03827798, a Phase 2 study of Hidradenitis Suppurativa, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
248 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LYS006, MAS825, LOU064 and VAY736 have an adequate clinical profile for further clinical development.

Primary Outcome

sHiSCR was defined as at least a 50 percent (%) reduction in abscess and inflammatory nodule (AN) counts, and no increase in draining fistula count related to baseline. The primary variable was modeled with the binomial distribution. A neutral non-informative Beta (1/3, 1/3) distribution was used as the prior for the response rate for all treatment groups. Based on the priors and the observed primary outcome, posterior distributions for the response rate for the investigational treatment and poo

Conditions Studied

Hidradenitis Suppurativa

Interventions

  • DRUG MAS825
  • DRUG CFZ533
  • DRUG Placebo to CFZ533
  • DRUG LYS006
  • DRUG Placebo to LYS006

Study Locations (20)

Other

  • Novartis Investigative Site - Graz
  • Novartis Investigative Site - Brussels
  • Novartis Investigative Site - Copenhagen
  • Novartis Investigative Site - Roskilde
  • Novartis Investigative Site - Antony
  • Novartis Investigative Site - Lyon
  • Novartis Investigative Site - Marseille
  • Novartis Investigative Site - Nice
  • Novartis Investigative Site - Reims
  • Novartis Investigative Site - Rouen
  • Novartis Investigative Site - Bochum

Florida

  • Olympian Clinical Research - Clearwater
  • Park Avenue Dermatology PA - Orange Park
  • University Of South Florida - Tampa

Georgia

  • Advanced Medical Research - Sandy Springs

Illinois

  • NorthShore University Health System - Evanston

Indiana

  • Dawes Fretzin Clinical Rea Group - Indianapolis

Pennsylvania

  • Penn State Milton S Hershey Medical Center - Hershey

South Carolina

  • Medical University of South Carolina MUSC - Charleston

Prague 1

  • Novartis Investigative Site - Prague

Trial Details

FieldValue
Enrollment Target 248 participants
Start Date 2019-02-27
Est. Completion 2026-12-11
Phase Phase 2
Novartis Pharmaceuticals

1,375 total trials

What the registry record for NCT03827798 still lists

NCT03827798 is an interventional study that assigns participants to a tested intervention. The registered 248 participants enrollment target is mid-sized for trials with a published cap, below the 593-participant average among 52 other Hidradenitis Suppurativa trials with a reported enrollment target (58% lower).

The record links to 1 condition, with Hidradenitis Suppurativa appearing as the primary indexed condition, and to 5 interventions - of which MAS825 is the first listed.

NCT03827798 names 20 study sites across 8 states, led by Other, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT03827798 about?

NCT03827798 is a clinical study titled "Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa". The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with moderate to severe hidradenitis suppurativa and to determine if CFZ533, LY...

What is the current status of trial NCT03827798?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2019-02-27. Estimated completion is 2026-12-11.

What conditions does trial NCT03827798 study?

This clinical trial studies the following conditions: Hidradenitis Suppurativa.

What interventions are being tested in trial NCT03827798?

The interventions under investigation include: MAS825 (DRUG), CFZ533 (DRUG), Placebo to CFZ533 (DRUG), LYS006 (DRUG), Placebo to LYS006 (DRUG).

Who is sponsoring clinical trial NCT03827798?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03827798 being conducted?

This trial has 20 study locations across Florida, Georgia, Illinois, Indiana, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hidradenitis Suppurativa

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03827798's enrollment target sits among peer trials

248 19th of 52 higher than 34 of 52 other Hidradenitis Suppurativa trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hidradenitis Suppurativa trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04577911 · 248 participants

    How is Social Connection Represented in the Brain?

  • NCT04777994 · 248 participants · Phase 1

    Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

  • NCT04792489 · 248 participants · Phase 2

    DALY II USA/ MB-CART2019.1 for DLBCL

  • NCT04830137 · 248 participants · Phase 1

    A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03827798, the US trial registry maintained by the National Library of Medicine. NCT03827798 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.